Welcome to our dedicated page for NewAmsterdam Pharma Company N.V news (Ticker: NAMS), a resource for investors and traders seeking the latest updates and insights on NewAmsterdam Pharma Company N.V stock.
NewAmsterdam Pharma Company N.V. reports news on its late-stage clinical biopharmaceutical work in oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C. The company’s principal program centers on obicetrapib, an oral, low-dose CETP inhibitor, evaluated alone and as a fixed-dose combination with ezetimibe as an adjunct to statin therapy.
Recurring updates include Phase 3 clinical data from programs such as BROADWAY, TANDEM, BROOKLYN and PREVAIL, safety and tolerability analyses, regulatory-review activity, financial results, corporate presentations and scientific-conference disclosures. NewAmsterdam also reports Nasdaq inducement grants and other equity-compensation actions tied to its public-company governance.
NewAmsterdam Pharma announced the appointment of John W. Smither as an independent director on its Board of Directors, effective February 6, 2023. He will also serve as chair of the Audit Committee. Smither brings extensive experience in the life sciences sector, having previously held CFO roles at Arcutis Biotherapeutics and Sienna Biopharmaceuticals. His expertise is expected to support the company's ongoing clinical trials for obicetrapib and enhance its strategic leadership post-public listing. The company has a robust capital position, with approximately $328 million from its recent business combination and significant licensing agreements in Europe.
NewAmsterdam Pharma Company announced positive topline results from its Phase 2 clinical trial ROSE2, evaluating the LDL-C lowering effects of obicetrapib in combination with ezetimibe. The trial achieved its primary endpoint with a statistically significant median LDL-C reduction of 59% in the combination group compared to 6% in the placebo group (p 0.0001). The combination was well-tolerated, and the company plans to advance to bioequivalence and Phase 3 trials. Obicetrapib is a promising CETP inhibitor aimed at improving treatment for patients needing additional LDL-C reduction alongside high-intensity statin therapy.
NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS) has appointed David Topper as Chief Financial Officer, effective January 1, 2023. Topper, who previously held leadership roles in capital markets, succeeds Louise Kooij, who becomes Chief Accounting Officer. The management team expressed confidence in Topper's expertise, particularly in navigating capital markets as NewAmsterdam advances obicetrapib, its key product for treating major cardiovascular diseases.
Founded in 2019, NewAmsterdam focuses on developing transformative therapies and has successfully completed a business combination in 2022.
NewAmsterdam Pharma Company N.V. completed its business combination with Frazier Lifesciences Acquisition Corporation on November 22, 2022. The transaction generated approximately $328 million in gross proceeds, including $235 million from an upsized private investment in public equity (PIPE). This financing is expected to extend the company's cash runway through 2026, covering pivotal Phase 3 trials for cardiovascular disease treatments. Trading under the new ticker symbols NAMS and NAMSW commenced on November 23, 2022.